| Literature DB >> 34277484 |
Maria Eduarda Pérez-de-Oliveira1, Thayná Melo de Lima Morais1, Márcio Ajudarte Lopes1, Oslei Paes de Almeida1, Willie F P van Heerden2, Pablo Agustin Vargas1,2.
Abstract
Ossifying fibromyxoid tumor (OFMT) is a rare mesenchymal soft tissue benign neoplasm with an uncertain line of differentiation, which arises most frequently in extremities. The head and neck region involvement is uncommon, with only ten intraoral cases published in the English-language literature. One additional case of OFMT is reported here, including a literature review of intraoral reported cases. A 45-year-old female patient presented a painless nodule involving the buccal mucosa of approximately two years duration, measuring nearly 1.3 cm in maximum diameter. The main histopathological features include ovoid to round cells embedded in a fibromyxoid matrix with a perpheral shell of lamellar bone. Immunohistochemically, the tumor showed immunoreactivity for vimentin and S100. No recurrence has been detected after 7 years of follow-up. Copyright:Entities:
Keywords: head and neck neoplasms; mouth; soft tissue neoplasms
Year: 2020 PMID: 34277484 PMCID: PMC8101660 DOI: 10.4322/acr.2020.216
Source DB: PubMed Journal: Autops Case Rep ISSN: 2236-1960
Figure 1Clinical features of the intraoral OFMT. A – A painless nodule in the anterior region of buccal mucosa with approximately 2 years of duration; B – A well-circumscribed submucosal nodule with a smooth surface and normochromic in the anterior region of buccal mucosa measuring 1.3 cm in maximum diameter.
Figure 2Photomicrographs of the intraoral ossifying fibromyxoid tumor. A – A well-circumscribed tumor with a complete fibrous capsule that extended fibrous septa, separating the hypercellular area from other areas (H&E, 1.44x); B – Peripheral shell of lamellar bone within the fibrous capsule (H&E, 5x); C – The cells range from small round to oval to fusiform shapes, with bland nuclei with fine chromatin and indistinct cytoplasm borders. The hypercellular area exhibited less intercellular matrix, often showing nuclear overlapping (H&E, 20x); D – Intermediate cellularity (H&E, 20x).
Figure 3Photomicrographs of the intraoral ossifying fibromyxoid tumor. A – Hypocellular area with abundant fibromyxoid matrix (H&E, 20x); B – Hyaline material in the center of the lesion resembling chondroid or osteoid material (H&E, 10x).
Immunohistochemical profile of the present intraoral ossifying fibromyxoid tumor
|
|
|
|
|---|---|---|
| AE1/AE3 | Negative | NA |
| GFAP | Negative | NA |
| S100 | Focally positive | Nuclear, mainly in hypocellular and hyaline areas |
| Vimentin | Positive | Cytoplasmic, all tumor cells |
| Calponin | Negative | NA |
| P63 | Negative | NA |
| CD34 | Negative | NA |
| INI-1 | Conserved | Nuclear, all tumor cells |
| Ki-67 | Low | Nuclear, < 5% of tumor cells in hypocellular and moderate areas, and < 10% in hypercellular area. |
IHC stain – immunohistochemical stain; NA – not applicable.
Figure 4Immunohistochemical reactions of the intraoral ossifying fibromyxoid tumor. A – Vimentin showed cytoplasmic positivity in all tumor cells (20x); B – Intact nuclear expression of INI-1 in all tumor cells (20x); C – S100 exhibit nuclear positivity in the tumor cells; D – mainly in fibromyxoid and hyaline areas (20x).
Figure 5Immunohistochemical reactions of the intraoral ossifying fibromyxoid tumor. A – Ki67 was low (< 5%); B – however, in the hypercellular area had an increased rate (< 10%) (immunohistochemistry, 20x).
Cases of intraoral ossifying fibromyxoid tumor reported in the English-language literature
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Schofield et al. | 39/M | Lip | ovoid masses | 1.5 | slow growing | NA (ITS: present in 12/13 cases) | 0-1/10 HPFs | No | ITS: S100 10/12, Desmin 7/10, SMA 4/8, fast myosin and sarcomere actin: 1/6, cytokeratin 1/7, vimentin 3/3, GFAP 1/3, Leu-7 1/3, | NA | NA (ITS: Follow-up were available on 8/13 (1-10 years – median: 7 years); NA (ITS: NED) |
| 41/M | Buccal mucosa | 1.5 | |||||||||
| Williams et al. | 67/F | Left mandibular vestibule | NA | 1.0 | 4 months | NA (in their series: present in 6/8 cases) | 1-2/10 HPFs | No | ITS: S100 (3/5), NSE (3/5), GFAP (2/5), Vimentin (5/5), Leu-7 3/5, SMA (2/5), MSA (2/5), NFP (0/5), EMA (0/5), Cytokeratin (0/5). | NA | 1.5 years; NED |
| 37/F | Soft palate | 4.5 | NA | 3 years; NED | |||||||
| Mollaoglu et al. | 13/M | Left mandibular vestibule | Hard, warm, painless mass covered by normal mucosa | 2.0 | 4 months | Yes | No | No | Vimentin +, SMA+ (focally), GFAP + (focally), S100−, EMA−, Pankeratin−, Desmin−, Leu-7−, CD34−. | NA | NA; NED |
| Miettinen et al. | NA/NA | Lower lip | NA | NA | NA | NA | NA | NA | ITS: Vimentin (33/33), S100 (67/71), CD10 (22/28), Keratin (6/45), Collagen IV (3/23), Desmin 4/40, GFAP (3/41), EMA (1/47), SMA (1/43), CD34 (0/38), HMB45 (0/13) | NA | NA |
| Sharif et al. | 14/F | Between buccal and gingival mucosa in the left anterior mandibular region | Nodular swelling with reddish surface. | 4.0 | 3 months | Yes | <2/10 HPFs | No | Vimentin +, S100 +, EMA −, cytokeratins − | NA | NA |
| Nonaka et al. | 21/F | Posterior mandibular gingiva | Painless exophytic mass with a reddish and lobulated surface. | 6.0 | 6 months | Yes | No | No | Vimentin +, S100 +, SMA −, MAS −, GFAP − | NA | 7 months; NED |
| Ohtaet al. | 26/M | Dorsal tongue |
|
|
| Yes |
|
| Vimentin+, S100+ (partially), GFAP−, cytokeratins−, αSMA−, calponin−, desmin−, CD68−, CD34−, p63−, Ki67 (7%) |
| |
| Titsinideset al. | 13/M | Retromolar trigone area | Painless mass, hard, nonmoveable covered by normal mucosa. | 0.8 | 7 months | Yes | No | No | Vimentin +, NSE+, MSA+, S100 −, GFAP −, SMA−, desmin −, AE1/AE3−, CD99−, CD34− | NA | 48 months; NED |
| index case | 45/F | Buccal mucosa | Painless nodule with smooth- surface. | 1.3 | 24 months | Yes | <2/10 HPFs | Mild pleomorphism | Vimentin +, S100 +, GFAP −, CD34 −, AE1/AE3 −, Calponin −, P63 −, Ki-67 5% | Conserved | 7 years; NED |
EMA – Epithelial membrane antigen; F – Female; GFAP – Glial fibrillary acidic protein; HPF – High-power field; INI-1 – gene INI-1; ITS - In their series; M – Male; MSA – Muscle specific actin; NA – Not available; NFP – Neurofilament protein; NED – No evidence of disease; NSE – Neuron specific enolase; SMA – Smooth muscle-actin; y – year.